Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 16/20 | 0.43 |
| ▸ | BCR | P11274 | 16/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.39 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4665705 | 0.95 | CYP3A4 (0.44) | ABL1BCRCYP3A4FGFR3 | |
| SCHEMBL4665825 | 0.94 | ABL1 (0.40) | ABL1BCRCYP3A4FGFR3CXCR1 | |
| SCHEMBL4666086 | 0.91 | HRH3 (0.44) | ABL1BCRCYP3A4FGFR3 | |
| SCHEMBL4665779 | 0.90 | CXCR1 (0.47) | ABL1BCRCYP3A4CXCR1FGFR1 | |
| SCHEMBL4666192 | 0.89 | ABL1 (0.42) | ABL1BCR | |
| SCHEMBL4663885 | 0.89 | FGFR3 (0.41) | ABL1BCRCYP3A4FGFR3FGFR1 | |
| SCHEMBL4667537 | 0.89 | EGFR (0.41) | ABL1BCRCYP3A4FGFR3CXCR1 | |
| SCHEMBL4665619 | 0.88 | ABL1 (0.43) | ABL1BCRCXCR1 | |
| SCHEMBL4664335 | 0.87 | ABL1 (0.43) | ABL1BCRCYP3A4FGFR3FGFR1 | |
| SCHEMBL4664327 | 0.87 | ABL1 (0.41) | ABL1BCRCYP3A4FGFR1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242681-A1 | N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors | ALTANA PHARMA AG (DE) | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242681-A1 | N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors | MAP3K19, MAP3K6, MAP3K20 | ABL1 24/4885BCR 402/4885CYP3A4 889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.